Joby Aviation closes $591 million stock offering with full underwriter option
LONDON - AOTI, Inc. (AIM:AOTI), a medical technology company focused on wound healing and amputation prevention, will publish its interim results for the six months ended June 30, 2025, on Monday, September 22, the company announced in a press release.
The company will host an analyst meeting at 9:30 a.m. BST at FTI Consulting’s London offices, with a webcast option available. A separate presentation for shareholders will take place via the Investor Meet Company platform at 11:30 a.m. BST on the same day.
AOTI specializes in Topical Wound Oxygen (TWO2) therapy, which the company states has shown effectiveness in clinical trials for treating diabetic foot ulcers. The therapy has received regulatory clearances in multiple markets including the U.S., Europe, UK, China, and Australia.
The company’s technology is designed to be administered by patients at home, which aims to improve access to care and treatment compliance.
Investors interested in attending the shareholder presentation can register through the Investor Meet Company platform, with the option to submit questions in advance or during the live event.
A recording of the analyst presentation will be made available on the company’s website following the meeting.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.